VIDEO: Real-world outcomes comparable for Dextenza vs. conventional topical regimen
Click Here to Manage Email Alerts
SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Benjamin Xu, MD, reports similar outcomes for patients using Dextenza compared with more conventional treatments after cataract surgery.
Using real-world data from the IRIS Registry, Xu and colleagues compared safety outcomes of patients who received Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) vs. a normal steroid regimen after cataract surgery.
“Both methods provided similar amounts of inflammation control, which was very minimal, especially after the first day,” Xu said. Steroid response between the two groups was also similar.
Overall, Dextenza is considered “safe and effective, similar to a more conventional treatment with topical eye drops,” as well as being convenient for patients postoperatively, Xu said.
Collapse
Xu B. Real-world safety analysis of 50,000 patients treated with intracanalicular dexamethasone insert using IRIS Registry. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Read more about
Click Here to Manage Email Alerts